|Headquarters||Suite 250 Austin, TX, United States|
|Key people||David G. Lowe (Co-Founder, CEO), CHARLES N YORK(CFO), F. ANDREW DORR (Chief Medical Officer) Joseph E. Tyler, Scott W. Rowlinson, Henry L. Hebel |
|Number of employees||31 |
Aeglea Biotherapeutics, Inc., a biopharmaceutical company, engages in developing engineered human enzymes for the treatment of inborn errors of metabolism and cancer. They develop enzyme-based therapeutics in the field of amino acid metabolism that we believe will transform the lives of patients with inborn errors of metabolism and cancer. Their engineered human enzymes are designed to degrade specific amino acids in the blood.
They are seeking to reduce toxic levels of amino acids in patients. In oncology, They are seeking to reduce amino acid blood levels below the normal range, where They believe They will be able to exploit the dependence of certain cancers on specific amino acids. They also have a strategic partnership with KBI Biopharma. Aeglea Biotherapeutics, Inc. was formerly known as Aeglea BioTherapeutics Holdings, LLC. The company was founded in 2013 and is based in Austin, Texas.
- It develops AERase/AEB1102, an amino acid for the degradation of arginine in the circulation, as well as for the treatment of hyperargininemia and cancer
- It also devlops AECase/AEB3103, an engineered and PEGylated human cysteine/cystine degrading enzyme that increases oxidative stress through glutathione depletion for treatment of hematologic and solid malignancies.
- The company also engages in developing AEMase/AEB2109, an engineered human enzyme that degrades methionine for the treatment of solid tumors
- AEB4104, an engineered human enzyme that degrades homocysteine in the circulation for the treatment of inborn error of metabolism homocystinuria.
Top 5 Recent Tweets
|October 13, 2018||The_CasualSmart||Aeglea BioTherapeutics, Inc. $AGLE EPS Estimated At $-0.41 https://t.co/xBchzCGwkH|
|October 13, 2018||bibeypost_stock||Aeglea BioTherapeutics, Inc. $AGLE Analysts See $-0.41 EPS - https://t.co/RMpevyEzBu|
|October 13, 2018||bibeypost_stock||$-0.41 EPS Expected for Aeglea BioTherapeutics, Inc. $AGLE - https://t.co/VwC361tDGE|
|October 11, 2018||InnovationUTS||Aeglea BioTherapeutics $AGLE to Present New Interim Phase 1/2 Clinical Trial Data in Arginase 1 Deficiency at 2018… https://t.co/o4VLOREIDF|
|October 11, 2018||StockTexts||$AGLE Aeglea BioTherapeutics, Inc. SEC Filing: Form SC 13G https://t.co/TgQBkw75hH|